Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $87.62 in the prior trading day, Astrazeneca plc ADR (NASDAQ: AZN) closed at $85.72, down -2.17%. In other words, the price has decreased by -$2.17 from its previous closing price. On the day, 4.35 million shares were traded. AZN stock price reached its highest trading level at $87.25 during the session, while it also had its lowest trading level at $85.38.
Ratios:
Our goal is to gain a better understanding of AZN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.17. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 0.89. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $97.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 270923218944 and an Enterprise Value of 159520997376. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.53, and their Forward P/E ratio for the next fiscal year is 18.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.41 while its Price-to-Book (P/B) ratio in mrq is 6.73. Its current Enterprise Value per Revenue stands at 3.247 whereas that against EBITDA is 9.399.
Stock Price History:
Over the past 52 weeks, AZN has reached a high of $87.68, while it has fallen to a 52-week low of $60.47. The 50-Day Moving Average of the stock is 6.02%, while the 200-Day Moving Average is calculated to be 18.87%.
Shares Statistics:
The stock has traded on average 4.06M shares per day over the past 3-months and 3546100 shares per day over the last 10 days, according to various share statistics. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.03% of the company’s shares, while institutions hold 16.26% stake in the company. Shares short for AZN as of 1723680000 were 5707953 with a Short Ratio of 2.10, compared to 1721001600 on 5801873.
Dividends & Splits
In the trailing 12 months, AZN’s forward annual dividend rate was 2.97, compared to 1.49 this year. Against a Trailing Annual Dividend Yield of 0.03389637The stock’s 5-year Average Dividend Yield is 2.39.
